Stock analysts at Zacks Research decreased their FY2024 EPS estimates for AbbVie in a research report issued to clients and investors on Wednesday, January 15th. Zacks Research analyst S. Ganoria now ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $173.7 which represents a slight increase of $2.35 or 1.37% from the prior close of $171.35. The stock opened at $171.45 and touched a ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...

Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Shares of AbbVie Inc. ABBV rallied 1.37% to $173.70 Thursday, on what proved to be an all-around rough trading session for ...

Shares of AbbVie Inc. ABBV slid 1.47% to $171.35 Wednesday, on what proved to be an all-around positive trading session for ...

Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...